ContractResearch and Commercial License Option Agreement • November 3rd, 2010 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances)
NOTE: Portions of this Exhibit are the subject of a Confidential Treatment Request by the Registrant to the Securities and Exchange Commission (the “Commission”). Such portions have been redacted and are marked with a “[***]” in the place of the redacted language. The redacted information has been filed separately with the Commission.
FIFTH AMENDMENT OF THE RESEARCH AND COMMERCIAL LICENSE OPTION AGREEMENTResearch and Commercial License Option Agreement • November 3rd, 2010 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances) • Delaware
This FIFTH AMENDMENT OF THE RESEARCH AND COMMERCIAL LICENSE OPTION AGREEMENT (this “Fifth Amendment”) is made and effective as of May 14, 2010 (the “Fifth Amendment Effective Date”) by and between SANGAMO BIOSCIENCES, INC., a Delaware corporation having its principal place of business at Point Richmond Tech Center, 501 Canal Boulevard, Suite A100, Richmond, California 94804 (“Sangamo”), and DOW AGROSCIENCES LLC, a Delaware limited liability company having its principal place of business at 9330 Zionsville Road, Indianapolis, Indiana 46268 (“DAS”) (each of Sangamo and DAS being a “Party,” and collectively, the “Parties”).
